Progenics Pharmaceuticals Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
34

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“Progenics Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Progenics Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “10” cancer drugs in clinical pipeline and majority of them are in phase-I.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Progenics Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Progenics Pharmaceuticals

  1.1 Business Overview

  1.2 Progenics Pharmaceuticals Cancer Pipeline Overview

 

2. Progenics Pharmaceuticals Cancer Drugs in Preclinical Phase

  2.1 Thorium-227 Radiolabelled Antibodies - Bayer/Progenics

  2.2 Cancer Radiopharmaceuticals - Progenics Pharmaceuticals

  2.3 Radiolabelled Carbonic Anhydrase IX Inhibitors - Progenics Pharmaceuticals

 

3. Progenics Pharmaceuticals Cancer Drugs in Phase-I

  3.1 Fluorine-18-DCFPyL

  3.2 Iofolastat I-123

  3.3 PSMA VRP

  3.4 Prostate Cancer Subunit Vaccine - Progenics

 

4. Progenics Pharmaceuticals Cancer Drugs in Phase-II

  4.1 PSMA ADC

  4.2 Iobenguane I-131 - Progenics Pharmaceuticals

 

5. Progenics Pharmaceuticals Cancer Drugs in Phase-III

  5.1 Technetium Tc 99m Trofolastat

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 Radiolabeled Seprase Inhibitors - Molecular Insight Pharmaceuticals

 

7. Discontinued in Cancer Drugs in Clinical Pipeline

  7.1 Melanoma Vaccine - Progenics

  7.2 99mTc-MIP-1405

  7.3 Cell Signalling Inhibitors - Progenics

 

8. Suspended in Cancer Drugs in Clinical Pipeline

  8.1 Ioflubenzamide I-131

Figure 1-1: Progenics Pharmaceuticals Cancer Pipeline by Phase (%)

Figure 1-2: Progenics Pharmaceuticals Cancer Pipeline by Phase (Number)

Figure 1-3: Progenics Pharmaceuticals Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Progenics Pharmaceuticals Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)